Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus bendamustine + rituximab vs bendamustine + rituximab in treatment-naive mantle cell lymphoma
2025-524241-27-00Phase 3Authorised
- Sponsor
- InnoCare Pharma
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Orelabrutinib + bendamustine + rituximab with Placebo + bendamustine + rituximab (2 arms). Primary endpoint: Progression-free survival (PFS) by IRC. Planned start Aug 2026; status: authorised.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2025-524241-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524241-27-00.